menu
    • menu
    [{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Not Applicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"LUCID-21-302","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Not Applicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Not Applicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Not Applicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Not Applicable"},{"orgOrder":0,"company":"iNGENu","sponsor":"FSD Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Lucid-21-302","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"iNGENu","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"iNGENu \/ FSD Pharma","highestDevelopmentStatusID":"6","companyTruncated":"iNGENu \/ FSD Pharma"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Not Applicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Not Applicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"FSD Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"FSD Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Ingenu CRO","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Lucid-21-302","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Quantum BioPharma \/ Ingenu CRO","highestDevelopmentStatusID":"6","companyTruncated":"Quantum BioPharma \/ Ingenu CRO"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Quantum BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quantum BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Quantum BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lucid-21-302","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Quantum BioPharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Quantum BioPharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Quantum BioPharma \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Lucid-21-302

    Menu

    Lucid-21-302

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Quantum BioPharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Quantum BioPharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quantum Biopharma Begins Dosing of Second Cohort in Lucid-21-302 Phase 1 Trial

                            Details : Lucid-21-302, a first-in-class, non-immunomodulatory, neuroprotective compound with hypercitrullination inhibition as unique mechanism of action is being investigated for multiple sclerosis.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 10, 2024

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Quantum BioPharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Quantum BioPharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Quantum Doses First Sentinel for Phase 1 Lucid-21-302 Trial in Australia

                            Details : Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis (MS).

                            Product Name : Lucid-21-302

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 29, 2024

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Quantum BioPharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            Quantum BioPharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Ingenu CRO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Quantum Biopharma Partners with Ingenu CRO For Multiple Sclerosis Study

                            Details : Ingenu will conduct a clinical study to observe and quantify disease progression in patients with primary progressive multiple sclerosis facilitating a future phase 2 with Lucid-21-302 (Lucid-MS).

                            Product Name : Lucid-MS

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 09, 2024

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Ingenu CRO

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            FSD Pharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            FSD Pharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FSD Pharma Receives HERC Approval for Phase 1 Trial of Lucid-21-302 in Australia

                            Details : Lucid-21-302, a first-in-class, non-immunomodulatory, neuroprotective compound with hypercitrullination inhibition as unique mechanism of action is being investigated for multiple sclerosis.

                            Product Name : Lucid-21-302

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 29, 2024

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            FSD Pharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            FSD Pharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FSD Pharma Receives Approval for Phase-1 Multiple Ascending Doses Clinical Trial

                            Details : Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis.

                            Product Name : Lucid-21-302

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 27, 2024

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            FSD Pharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            FSD Pharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FSD Pharma Submits Phase-1 Trial Application for Lucid-21-302 in Australia for Review

                            Details : Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis (MS).

                            Product Name : Lucid-21-302

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 07, 2024

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            iNGENu

                            Country arrow
                            BIO CEO & Investor
                            Not Confirmed

                            iNGENu

                            Country arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : FSD Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            FSD Pharma Signs Agreement to Assess Lucid-21-302 Safety in Healthy Adults

                            Details : The agreement aims to assess the safety and pharmacokinetics of Lucid-21-302, a neuroprotective compound with a novel mechanism for treating multiple sclerosis.

                            Product Name : Lucid-21-302

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 27, 2024

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : FSD Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            FSD Pharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            FSD Pharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multipl...

                            Details : Lucid-MS (lucid-21-302) is a first-in-class neuroprotective compound with a novel mechanism of action which, in preclinical models, has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases.

                            Product Name : Lucid-MS

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 18, 2023

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            FSD Pharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            FSD Pharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for th...

                            Details : Lucid-MS (lucid-21-302) is a patented first-in-class, small molecule inhibitor of hypercitrullination, New Chemical Entity and a neuroprotective compound with a novel mechanism of action for the treatment of Multiple Sclerosis.

                            Product Name : Lucid-MS

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 10, 2023

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            FSD Pharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed

                            FSD Pharma

                            Canada arrow
                            BIO CEO & Investor
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of...

                            Details : Lucid-MS (lucid-21-302) is a first-in-class neuroprotective compound with a novel mechanism action which, in preclinical models, has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases.

                            Product Name : Lucid-MS

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 17, 2023

                            Lead Product(s) : Lucid-21-302

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth